基于8937例患者汇总安全性评估的帕博利珠单抗单药治疗安全性特征
该汇总分析纳入31项晚期癌症临床试验的8937例接受帕博利珠单抗单药治疗的患者,评估不良事件及免疫介导不良事件和输注反应。结果显示不良事件发生率为96.6%,3-5级不良事件发生率为50.6%,免疫介导不良事件和输注反应发生率为23.7%。结论认为帕博利珠单抗在不同适应症中具有一致的安全性特征。
要点
- 8937例患者中不良事件发生率96.6%,3-5级不良事件发生率50.6%。
- 免疫介导不良事件和输注反应发生率23.7%,3-5级免疫介导不良事件发生率6.3%。
- 免疫介导不良事件中位起病时间85天(范围13-163天)。
核心结论
- 该31项临床试验的汇总分析显示,帕博利珠单抗在不同适应症中具有一致的安全性特征。
研究设计与样本
- 汇总31项晚期癌症临床试验中接受至少一剂帕博利珠单抗(200 mg每3周,或10 mg/kg每2周或每3周,或2 mg/kg每3周)单药治疗的患者安全性数据进行分析。
- 共纳入8937例患者,涵盖19种癌症类型,中位给药次数7次(范围1-59次),中位治疗持续时间4.1个月(范围0.03-40.1个月)。
主要发现
- 不良事件发生于96.6%的患者,3-5级不良事件发生于50.6%的患者。
- 不良事件导致12.7%的患者停用帕博利珠单抗,导致5.9%的患者死亡。
- 免疫介导不良事件和输注反应发生于23.7%的患者(4.6%经历多种免疫介导不良事件/输注反应),导致3.6%的患者停药、0.2%的患者死亡。
- 3-5级免疫介导不良事件发生于6.3%的患者,严重免疫介导不良事件和输注反应发生于6.0%的患者。
- 免疫介导不良事件中位起病时间为85天(范围13-163天);2657例免疫介导不良事件中,22.3%初始接受泼尼松≥40 mg/天或等效剂量治疗,8.3%初始接受较低剂量类固醇治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pembrolizumab has a manageable safety profile as described in its label, which was primarily based on 2799 patients who participated in clinical trials for melanoma or non-small cell lung cancer. Here, we evaluated the safety of pembrolizumab in a broader population of patients from 31 advanced cancer clinical trials across 19 cancer types. METHODS: Safety was analyzed in patients who received at least one dose of pembrolizumab (200 mg every 3 weeks [Q3W], 10 mg/kg Q2W or Q3W, or 2 mg/kg Q3W). Adverse events (AEs) and immune-mediated AEs and infusion reactions were evaluated. RESULTS: Safety data from 8937 patients in 31 trials of pembrolizumab monotherapy were pooled (median, seven administrations; range, 1-59). Median duration on treatment was 4.1 months (range, 0.03-40.1). AEs occurred in 96.6% of patients. Grade 3-5 AEs occurred in 50.6% of patients. AEs led to pembrolizumab discontinuation in 12.7% of patients and death in 5.9%. Immune-mediated AEs and infusion reactions occurred in 23.7% of patients (4.6% experienced multiple immune-mediated AEs/infusion reactions) and led to pembrolizumab discontinuation in 3.6% and death in 0.2%. Grade 3-5 immune-mediated AEs occurred in 6.3% of patients. Serious immune-mediated AEs and infusion reactions occurred in 6.0% of patients. Median time to immune-mediated AE onset was 85 days (range, 13-163). Of 2657 immune-mediated AEs, 22.3% were initially treated with prednisone ≥ 40 mg/day or equivalent, and 8.3% were initially treated with lower steroid doses. CONCLUSIONS: This pooled analysis of 31 clinical trials showed that pembrolizumab has a consistent safety profile across indications.
引用
- Brahmer JR, Long GV, Hamid O, et al. Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients. Eur J Cancer. 2024. PMID: 38295556. doi:10.1016/j.ejca.2024.113530
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。